M Doortje Reijman, D Meeike Kusters, Jaap W Groothoff, Klaus Arbeiter, Eldad J Dann, Lotte M de Boer, Sarah D de Ferranti, Antonio Gallo, Susanne Greber-Platzer, Jacob Hartz, Lisa C Hudgins, Daiana Ibarretxe, Meral Kayikcioglu, Reinhard Klingel, Genovefa D Kolovou, Jun Oh, R Nils Planken, Claudia Stefanutti, Christina Taylan, Albert Wiegman, Claus Peter Schmitt
Homozygous familial hypercholesterolaemia is a life-threatening genetic condition, which causes extremely elevated LDL-C levels and atherosclerotic cardiovascular disease very early in life. It is vital to start effective lipid-lowering treatment from diagnosis onwards. Even with dietary and current multimodal pharmaceutical lipid-lowering therapies, LDL-C treatment goals cannot be achieved in many children. Lipoprotein apheresis is an extracorporeal lipid-lowering treatment, which is used for decades, lowering serum LDL-C levels by more than 70% directly after the treatment...
March 27, 2024: Atherosclerosis